Portola announces phase 3 ANNEXA(TM) study of andexanet alfa and eliquis (apixaban)
Portola Pharmaceuticals announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and FDA-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. October 01, 2014